BioSpace News Archive

Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2022 financial results on Thursday, October 7, 2021, after the market closes.

Applied Genetic Technologies Corporation today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021.

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, will present three posters at the 26th Annual Congress of the World Muscle Society (WMS).

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

A Fact.MR survey offers comprehensive analysis on fluidized-bed bioreactors market. Increasing investment in healthcare sector will enable the market to register spurring sales.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that the poster “A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma” is now available at the ESMO congress website and on the Company’s website.

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol has made headway with COVID-19 treatment development in more broaden clinical trial patients permitted in inclusion severity as well as future marketing expansion by signing a new international MOU for cooperation and development of the new drugs in 23 European countries.

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, presented encouraging initial clinical data on samuraciclib, an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical Oncology Congress.